 |
|
|
|
|
|
|
Program Objectives
At the conclusion of this symposium, participants should be able to:
- Describe the role of the autonomic nervous system in ventricular arrhythmogenesis
and sudden cardiac death
- Discuss the role of genomic predictors of sudden death
- Explain the role of genotyping in various genetic arrhythmia syndromes
- Identify the techniques and pitfalls in ablating VT originating from the aortic
cusps
- Describe the current status and future role for implantable cardioverterdefibrillators
in the management of sudden cardiac death
- Describe the role and usefulness of various imaging techniques (including MRI, contrast
CT and voltage mapping) in patients with VT
- Review treatment options including ablation for various unusual disease states-hypertrophic
cardiomyopathy, Brugada syndrome, cardiac sarcoid and ARVC.
- Describe how to improve the treatment of patients with ventricular arrhythmias and
structural heart disease
- Review the epicardial substrate of patients with VT and ARVC/D
- Describe the safety and efficacy of pericardial access, catheter mapping and ablation
of epicardial ventricular tachycardia
- Discuss the use of hemodynamic support during VT ablation
- Explain ways to recognize VT from an intraseptal substrate including the use of
unipolar voltage mapping, intracardiac echocardiography and other imaging
- Review treatment of VT associated with intraseptal substrate including new technologies
(HIFU, needle intramural ablation and intracoronary ethanol ablation)
- Identify new ablation energy sources and catheter designs for performing ablation
of ventricular tissue
- Review the status of several ongoing multicenter trials and discuss which questions
need to be answered by trials in the future
|
|
|
|
|